Fig. 5.
![Fig. 5. Effect of piceatannol on PAC-1 binding to platelets. Human platelets were pretreated for 10 minutes at room temperature with control DMSO vehicle or piceatannol at 1, 10, or 30 μg/mL. They were then stimulated with the desired agonist ([○] PBS control, [▴] 0.1 μmol/L ADP, [□] 1 μmol/L ADP, [•] 10 μmol/L ADP, [⧫] 0.2 μmol/L PMA) and incubated with FITC-labeled PAC-1 antibody. The level of PAC-1 bound is expressed as a percentage of maximal PAC-1 binding obtained when the DMSO-pretreated platelets were stimulated with the highest concentration of agonist (either 10 μmol/L ADP for the ADP-treated samples or 0.2 μmol/L PMA for the PMA-treated samples). Results shown are the mean ± SE values from three separate experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/93/8/10.1182_blood.v93.8.2645/5/blod40813005x.jpeg?Expires=1723915998&Signature=b1EqETLUopM2~-u1UgRC-m85DU9bDfUaYJFWCpoX5UpyzYCzIq7VsXAg3UZQKILINjkg4zlPZA9ZMZWwjEU3Nirg0FHF2Ex61Xlv7~NOgwrGK6prJkR5V2yI-Yz2ZibsP7et9PH~5ouybPNLLZl76i3QbQres~tWnEPOV6pZJKNVQ21CyW8EBhQDo~fT4Cf8-bi3CLIaW4l9c3aXyOxuN3tsOpcEOwLugDAWuJE1f3KfgcUXsgjV7otJQhUePxg-Jt~I8LZ5u08RSnTrBrNbei0ISSN5R9l6wpxQVHCenefA58WoPmwKz8VOR6U~JpTnFw3g~kTSpYgFe7-wyu-nKg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Effect of piceatannol on PAC-1 binding to platelets. Human platelets were pretreated for 10 minutes at room temperature with control DMSO vehicle or piceatannol at 1, 10, or 30 μg/mL. They were then stimulated with the desired agonist ([○] PBS control, [▴] 0.1 μmol/L ADP, [□] 1 μmol/L ADP, [•] 10 μmol/L ADP, [⧫] 0.2 μmol/L PMA) and incubated with FITC-labeled PAC-1 antibody. The level of PAC-1 bound is expressed as a percentage of maximal PAC-1 binding obtained when the DMSO-pretreated platelets were stimulated with the highest concentration of agonist (either 10 μmol/L ADP for the ADP-treated samples or 0.2 μmol/L PMA for the PMA-treated samples). Results shown are the mean ± SE values from three separate experiments.
